SPDR S&P Biotech ETF (XBI) Holdings Raised by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,630 shares of the exchange traded fund’s stock after purchasing an additional 2,535 shares during the quarter. Tocqueville Asset Management L.P. owned 0.16% of SPDR S&P Biotech ETF worth $8,689,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of XBI. FUKOKU MUTUAL LIFE INSURANCE Co grew its stake in SPDR S&P Biotech ETF by 6.0% during the 2nd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 126,100 shares of the exchange traded fund’s stock valued at $12,003,000 after purchasing an additional 7,100 shares in the last quarter. Beaumont Financial Partners LLC grew its position in shares of SPDR S&P Biotech ETF by 1,099.6% in the 2nd quarter. Beaumont Financial Partners LLC now owns 36,025 shares of the exchange traded fund’s stock worth $3,429,000 after acquiring an additional 33,022 shares in the last quarter. Belpointe Asset Management LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 2nd quarter worth approximately $3,603,000. Strs Ohio grew its position in shares of SPDR S&P Biotech ETF by 2.4% in the 2nd quarter. Strs Ohio now owns 43,000 shares of the exchange traded fund’s stock worth $4,093,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Verity Asset Management Inc. grew its position in shares of SPDR S&P Biotech ETF by 661.7% in the 2nd quarter. Verity Asset Management Inc. now owns 25,594 shares of the exchange traded fund’s stock worth $2,436,000 after acquiring an additional 22,234 shares in the last quarter.

Shares of XBI opened at $78.19 on Friday. SPDR S&P Biotech ETF has a 52 week low of $73.97 and a 52 week high of $101.55.

TRADEMARK VIOLATION NOTICE: “SPDR S&P Biotech ETF (XBI) Holdings Raised by Tocqueville Asset Management L.P.” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/12/08/spdr-sp-biotech-etf-xbi-holdings-raised-by-tocqueville-asset-management-l-p-2.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: How to read a candlestick chart

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply